Clearing the Way in Atopic DermatitisA Case-Based Update on Pediatric Patients
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.
Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2020;34(12):2717-2744.
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.
Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(5):657-682.
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.
Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(6):850-878.
International Eczema Council
Founded in late 2014, the International Eczema Council (IEC) is a global nonprofit organization led by dermatology experts on atopic dermatitis. The IEC is dedicated to increasing the understanding of atopic dermatitis and promoting its optimal management through research, education, and patient/family care.
Clinical Assessment Tools
Children’s Dermatology Life Quality Index (CDLQI)
CDLQI is 10-question patient-reported assessment tool designed to measure impact of any skin disease on the lives of children ages 4-16. (Lewis-Jones MS, Finlay AY. Br J Dermatol. 1995;132(6):942-949).
Patient-Oriented Eczema Measure (POEM)
The POEM is a patient-oriented, self-assessed measurement tool for monitoring aspects of atopic dermatitis in routine clinical practice or in the clinical trial setting. (Charman CR, et al. Arch Dermatol. 2004;140(12):1513-1519).
Atopic Dermatitis Overview and Pathogenesis
Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts.
Paternoster L, et al. J Allergy Clin Immunol. 2018:141(3):964-971.
Pathogenesis of atopic dermatitis.
Peng W, Novak N. Clin Exp Allergy. 2015;45(3):566-574.
Patient Burden and Comorbidities
The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis.
Chamlin SL, et at. Arch Pediatr Adolesc Med. 2005;159(8):745-750.
Association of atopic dermatitis and mental health outcomes across childhood: a longitudinal cohort study.
Kern C, et al. JAMA Dermatol. 2021;157(10):1200-1208.
‘His first word was “cream.”' The burden of treatment in paediatric atopic dermatitis—a mixed methods study.
O’Connor C, et al. Dermatol Ther. 2022;35(3):e15273.
Association between atopic dermatitis and suicidality: a systematic review and meta-analysis.
Sandhu JK, et al. JAMA Dermatol. 2019;155(2):178-187.
Increasing severity of early-onset atopic dermatitis, but not late-onset, associates with development of aeroallergen sensitization and allergic rhinitis in childhood.
Schoos AMM, et al. Allergy. 2022;77(4):1254-1262.
Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study.
Silverberg JI, et al. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2.
Comorbidities and the impact of atopic dermatitis.
Silverberg JI. Ann Allergy Asthma Immunol. 2019;123(2)144-151.
Management of Atopic Dermatitis
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303.
Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial.
Blauvelt A, et al. JAMA Dermatol. 2021;157(9):1047-1055.
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.
Drucker AM, et al. Br J Dermatol. 2018;178(3):768-775.
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomized controlled phase 3 trials.
Guttman-Yassky E, et al. Lancet. 2021;397(10290):2151-2168.
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial.
Paller AS, et al. J Am Acad Dermatol. 2020;83(5):1282-1293.
Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial.
Silverberg JI, et al. JAMA Dermatol. 2020;156(8):863-873.
Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial.
Simpson EL, et al. JAMA Dermatol. 2020;156(1):44-56.
A Case-Based Update on Pediatric Patients
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Improving Outcomes for Patients with COPD
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A New Era in Precision Medicine
Pathophysiology to the Management of Moderate-to-Severe Disease
Evolving Best Practices to Optimize Outcomes
Consensus and Controversies on the Road to Precision Medicine
New Strategies to Target Remission and Individualize Comprehensive Care
Targeting Immune Dysregulation and Delivering Comprehensive Care
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
Looking Beyond Barriers to Optimize Therapy
Debates and Discussions About Personalizing Patient Management
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
From Guideline Recommendations to Daily Clinical Decision-Making
Improving Patient Outcomes Through Shared Clinical Decision Making
Debates and Discussions About Pustular Disease Subtypes
Collaborative Care for Better Patient Outcomes
Improving Patient Outcomes Through Shared Clinical Decision Making
Digging Deep on Shared Decision-Making
Clinical Resource Center
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
Mechanistic Insights and Emerging Treatment Options
A Focus on Exacerbation Prevention
Best Practices for Primary Care
Evolving Best Practices for Patient Management
Pathophysiology, Multimodal Management, and Shared Clinical Decision Making
Shared Decision-making in the Era of Biologics
New Pathways to Patient Management
From Comprehensive Patient Evaluations to Individualized Evidence-based Care
Preventing COPD Exacerbations to Improve Outcomes
A Whole Patient Case Series
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
New Avenues to the Management of Severe Asthma
Evolving Best Practices for Pediatric Patients
A Case-Based Update
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
A Multidisciplinary Look at Early Diagnosis and Management
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
New Pathways to Optimize Patient Outcomes
Debates and Discussions About New Upstream Treatment Avenues
An Interactive Educational Journey
Test Your Mastery!
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Practical Updates on the 2023 GOLD Guidelines
Best Practices for Screening, Diagnosis, and Management
Incorporating New Data and Updated Guidelines Into Daily Practice
Focus on Psoriasis
From the Airway Epithelium to Improved Patient Outcomes
Exercising Best Practices for Hospitalized Patients
Accelerating Diagnosis and Treatment